This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos
by Zacks Equity Research
Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.12%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $293.21, marking a -1.12% move from the previous day.
3 Medical Stocks to Buy in 2022 for Long-Term Resilience
by Indrajit Bandyopadhyay
Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.
Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.
Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic
by Zacks Equity Research
The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers.
Top Analyst Reports for NVIDIA, Pfizer & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).
Here's Why You Should Invest in Vertex (VRTX) Stock Now
by Zacks Equity Research
Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.14%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.23, moving -1.14% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $302.02, marking a +0.46% move from the previous day.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line
by Zacks Equity Research
bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $292.80 in the latest trading session, marking a +0.13% move from the prior day.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
by Zacks Equity Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy
by Zacks Equity Research
Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.
Why Low Volatility ETFs are Beating the Market
by Neena Mishra
We highlight 3 popular low and minimum volatility ETFs
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Vertex Pharmaceuticals (VRTX) Stock Moves -1.01%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $283.45 in the latest trading session, marking a -1.01% move from the prior day.
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
Minimum Volatility & Value ETFs for Turbulent Markets
by Neena Mishra
We discuss how factor ETFs can help investors in the challenging market environment
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
by Zacks Equity Research
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
by Zacks Equity Research
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $287.67, marking a +0.99% move from the previous day.
Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTC
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $284.86 in the latest trading session, marking a +1.49% move from the prior day.